This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs requiring evaluation by a licensed healthcare professional. Eligibility is not guaranteed. Compounded medications are not FDA-approved finished products. Always consult a qualified clinician before starting any prescription treatment program.
The Word Most Telehealth Review Sites Skip Over
Every review of Wellorithm and similar platforms mentions that they offer “compounded semaglutide.” Most of them move on within a sentence. I'm not going to do that — because in 2026, the word “compounded” carries a lot more weight than it did when these programs first launched, and people making a decision about whether to enroll deserve to understand what it actually means.
This is the article I'd want to read before signing up for any compounded GLP-1 telehealth program. It covers what compounding is, how the rules changed when the drug shortage ended, what to verify about the specific medication being prescribed to you, and the questions worth asking your clinician before your first shipment arrives.
If you've already read my full Wellorithm review and want the deeper background on the medication side, this is it: Wellorithm Review 2026: What I Found After Researching the GLP-1 Telehealth Program.
Compounded vs. FDA-Approved: The Actual Distinction
Semaglutide is the active ingredient in two FDA-approved products: Wegovy (approved for weight management) and Ozempic (approved for type 2 diabetes management). Tirzepatide is the active ingredient in Zepbound (approved for weight management) and Mounjaro (approved for type 2 diabetes). These brand-name medications went through the FDA's full drug approval process — clinical trials, safety review, efficacy data, manufacturing quality controls.
Compounded semaglutide and compounded tirzepatide are different. They are prepared by licensed compounding pharmacies based on individual patient prescriptions. They use the same active ingredient, but as Wellorithm's own site states: “Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality.”
This is not a reason to rule them out. Compounding serves a legitimate and long-standing role in medicine — it allows pharmacies to prepare medications that meet individual patient needs when commercially available products aren't appropriate or accessible. For years during the GLP-1 shortage, compounding was genuinely filling an access gap for patients who could not get the brand-name version. The issue is that the context has changed, and the rules have changed with it.
What Changed When the Shortage Ended
The FDA resolved the tirzepatide shortage in late 2024 and the semaglutide shortage in early 2025. That resolution matters because the legal framework that had permitted mass-scale GLP-1 compounding was tied directly to the shortage designation. Once shortages are resolved, federal compounding rules restrict producing medications that are essentially copies of commercially available FDA-approved drugs.
The FDA has issued warning letters to telehealth companies since the shortage resolved, and the agency has been publicly active in distinguishing between patient-specific compounding for individual clinical need versus mass-marketed compounded products. The legal landscape for any compounded GLP-1 program in 2026 depends partly on how the specific pharmacy is structured — whether it operates under Section 503A (patient-specific) or Section 503B (outsourcing facility) of the Federal Food, Drug, and Cosmetic Act — and whether its current operations comply with post-shortage regulatory guidance.
An April 2026 report examining compounded GLP-1 products found quality variation concerns in a meaningful portion of samples tested, according to topline findings pending full peer-reviewed publication. This doesn't mean every compounded product is problematic. It means the due diligence questions have more weight now than they did two years ago.
The Salt Form Question: One Specific Thing to Verify
One detail that came up repeatedly in my research and that most reviews don't address: not all compounded semaglutide uses the same molecular form of the active ingredient. The FDA-approved brand-name products use the base form of semaglutide. Some compounders have used semaglutide sodium or semaglutide acetate — salt forms whose clinical equivalence to the base molecule has not been established in published human studies.
Before starting a compounded GLP-1 program, it's worth asking your prescribing clinician and the dispensing pharmacy: What is the exact molecular form of the active ingredient being compounded? It's a specific question and a legitimate one to ask.
Injectable vs. Oral Dissolving Tablet: What the Evidence Says
Wellorithm and several other platforms now offer compounded oral dissolving tablet (ODT) formats — sublingual lozenges that dissolve under the tongue — as an alternative to injectable semaglutide or tirzepatide. For patients who are needle-averse, this is appealing.
Here's what the evidence picture looks like as of 2026: FDA-approved injectable semaglutide (Wegovy) has robust clinical trial data from the STEP trial program, which established efficacy in FDA-reviewed trials. The FDA has also approved an oral semaglutide pill (Rybelsus/Wegovy pill) using a specific formulation that optimizes absorption when taken on an empty stomach. Compounded sublingual or buccal GLP-1 formulations do not currently have published human clinical trials establishing their bioavailability or efficacy. The absorption data that exists for compounded ODT formats is preclinical — in vitro or animal data — not human trial data. Your clinician should be able to explain how the specific ODT being prescribed is expected to behave and on what basis.
This isn't a dealbreaker, but it's a meaningful difference from a clinical evidence standpoint that's worth understanding before you choose a format.
Questions to Ask Your Clinician Before Starting
A telehealth intake is a real clinical evaluation. These questions are worth raising:
About the medication: What is the exact molecular form of the active ingredient? Is this the same form used in the FDA-approved reference product? What is the dose escalation schedule? What should I do if I experience significant side effects?
About the pharmacy: What is the name of the compounding pharmacy fulfilling my prescription? Is it a 503A or 503B facility? Is it licensed to dispense in my state?
About your eligibility: Do I have personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 — known contraindications for GLP-1 class medications? How will this medication interact with my current medications?
About monitoring: What follow-up is included? How often will we review my response and adjust dosing?
How This Fits Into a Bigger Picture
Understanding what “compounded” means is the first step. It's not a reason to avoid these programs — for the right patient who is eligible, physician-supervised GLP-1 therapy addresses mechanisms that supplements and behavioral approaches simply cannot match. The class of drugs works. The clinical trial data for FDA-approved semaglutide (Wegovy) established meaningful weight loss outcomes in well-designed trials. The question is about the specific product being prescribed to you and whether the platform and pharmacy meet the verification standards you're entitled to apply.
If you're still in the research phase and comparing your options beyond Wellorithm, my safety and side effects article covers what to expect: Wellorithm Semaglutide Side Effects: What to Know Before You Start.
For readers who came to this article from my gelatin trick research — the comparison between behavioral appetite tools and prescription intervention isn't one I'd frame as “one replaces the other.” They're different tiers of intervention for different situations. The gelatin work lives here: Does the Gelatin Trick Work? I Tried It for 30 Days. If you want a non-prescription GLP-1 support supplement comparison, this review covers that category: Sprout Health GLP-1 Supplement Review.
Frequently Asked Questions
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide is prepared by a licensed compounding pharmacy based on an individual prescription. Wegovy is an FDA-approved finished product. They contain the same active ingredient but are not interchangeable from a regulatory standpoint.
Is compounded semaglutide still legal in 2026?
The legal landscape changed significantly after the FDA resolved the semaglutide shortage in early 2025. Patient-specific compounding for individual clinical needs remains a recognized category under federal law, but mass-marketed compounded copies face different regulatory scrutiny. Confirm current availability and status directly with any platform you are considering and with your prescribing clinician.
What questions should I ask before starting compounded semaglutide?
Key questions include: What is the exact molecular form of the active ingredient? Is the pharmacy a 503A or 503B facility? Is it licensed in my state? How are dose escalations handled? What monitoring is included? How does this interact with my current medications?
What is the difference between injectable and oral dissolving tablet GLP-1?
Injectable semaglutide has established clinical data in FDA-approved form from published trials. Compounded oral dissolving tablet formats currently do not have published human clinical trials establishing their bioavailability or efficacy. Your clinician can help evaluate the appropriate format for your situation.
Leave a Reply
You must be logged in to post a comment.